DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising thes...

Full description

Saved in:
Bibliographic Details
Main Authors FANG, TIANAN, PINTO, DONALD, J.P., PINTO, EWING, WILLIAM, R, SMITH II, LEON, M, CORTE, JAMES, R, PABBISETTY, KUMAR, B, DILGER, ANDREW, K, GILLIGAN, PAUL, J, YANG, WU, WANG, YUFENG
Format Patent
LanguageEnglish
Serbian
Published 29.09.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Bibliography:Application Number: RS2017P000501